Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.

Unlike GLP-1s, PCSK9 inhibitors are a near "free lunch." Discovered from a genetic mutation in a population with virtually no heart disease, these drugs dramatically lower bad cholesterol with minimal trade-offs, making them an ideal preventative tool.

For CNS diseases, where animal models are notoriously unreliable predictors of efficacy, the most pragmatic R&D model is to quickly move promising new chemical entities into human trials. The focus shifts from extensive preclinical validation to early biological experimentation in humans for proof-of-concept.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The success of enlicitide wasn't a single discovery but was built on a generation's worth of investment in biocatalysis at Merck, starting in the 90s. This demonstrates that world-changing innovation is a slow, consistent build-up of incremental learnings from prior projects, not a sudden eureka moment.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Macrocyclic peptides are large enough to disrupt difficult protein-protein interactions (like biologics) but small enough to be orally bioavailable (like small molecules). This new modality can tackle targets previously undruggable by conventional small molecules, creating a best-of-both-worlds therapeutic.

Recent Phase 3 data show oral small molecules succeeding in complex indications. Roche's phenobrutinib met its endpoint in progressive multiple sclerosis, and Bridge Biopharma's Imfegratinib improved height velocity in achondroplasia. This signals a potential shift toward more convenient, patient-friendly oral therapies in areas historically reliant on injectables.

The failure of Mirati's 1133 agent, which was effective preclinically but failed in trials, shows that impressive lab results are not enough. A drug's clinical viability hinges on pharmacological properties like bioavailability, which can prevent an effective compound from reaching its target in patients.